Soft tissue and bone sarcomas are malignancies of mesenchymal origin, and more than 50 subtypes are defined. For most sarcomas, locally advanced or unresectable disease is still treated with cytotoxic chemotherapy. Recently, our understanding of subtype-specific cancer biology has expanded, and it has revealed distinct molecular alterations responsible for tumor initiation and progression. These findings have motivated the development of targeted therapies that are being evaluated in subtype-specific or biomarker-driven clinical trials. Indeed, the spectrum of targeted drug development in sarcoma now spans many of the most active paradigms in cancer research and includes agents that target cancer-related vulnerabilities in receptor tyrosine kinases and intracellular signaling pathways, epigenetics, metabolism, nuclear-cytoplasmic transport, and many others. Our understanding of the sarcoma immune microenvironment and heterogeneous mechanisms of tumor immune evasion has also expanded. Although a subset of sarcomas appears inflamed and responsive to immune checkpoint blockade with programmed death 1 (PD-1) targeted agents, novel immunotherapies and combinations likely will be needed for most subtypes. A variety of approaches-including targeting immune checkpoints other than PD-1; modulating tumorassociated macrophage phenotype from tumor-promoting to tumor-suppressive status; using cellularbased therapies, such as chimeric antigen and high-affinity T-cell receptors to deepen the adaptive immune response; and reinvigorating older approaches, such as vaccines and oncolytic virus-based treatments-are being investigated. The goal of these new approaches is to harness subtypespecific insights into cancer and immune biology to bring more effective and less toxic treatments to the clinic for the benefit of patients with sarcoma.
INTRODUCTION
Soft tissue and bone sarcomas comprise a heterogeneous malignancy of more than 50 subtypes. Although most harbor distinct biologic features, the primary treatment approach for advanced disease often incorporates chemotherapy. Recently, efforts have been made to develop targeted therapeutic agents that reflect subtypespecific cancer and immune biology, building on the paradigm established by imatinib in stem cell factor (KIT)/platelet-derived growth factor receptor alpha (PDGFR-a)-mutant gastrointestinal stromal tumors (GISTs). 1 Nonetheless, the rarity of sarcoma poses challenges for drug development, because targeted agents are best evaluated in subtype-or biomarker-specific trials. Here, we highlight a subset of emerging treatments and emphasize the underlying cancer biology. These agents are depicted schematically (Fig 1) , and lists of ongoing trials with targeted (Table 1) and immune-based (Tables 2 and 3) approaches are provided.
EXTENDING THE FRONTIER OF TARGETED THERAPY IN SARCOMA
Receptor Tyrosine Kinases and Signaling Pathways Pazopanib, an oral small-molecule receptor tyrosine kinase inhibitor (RTKi) active upon the proangiogenic PDGFR-a, PDGFR-b, and vascular endothelial growth factor receptor (VEGFR), as well as olaratumab, a monoclonal antibody that inhibits PDGFR-a, represent the only two targeted therapies to receive regulatory approval across several sarcoma subtypes, which highlights the relevance of RTKs for sarcomagenesis. 2 Interestingly, pazopanib appeared inactive in liposarcoma (LPS). 3 We have noted marked heterogeneity in activated RTKs across sarcoma subtypes. 4 For example, in well-/de-differentiated (WD/DD) LPS, phosphorylated PDGFR-a/-b, insulin-like growth factor 1 receptor (IGF1-R), and hepatocyte growth factor receptor (HGFR/ MET) are strongly expressed, and siRNA knockdown or pharmacologic inhibition of multiple RTKs more effectively inhibited proliferation than abrogation of one. 4, 5 These observations suggest that a more broadly targeted RTKi may sometimes be more effective. 6 Sitravatinib, an RTKi with activity on MET, IGF1-R, PDGFR-a/-b, and VEGFR, among others, is being evaluated in WD/DD LPS (ClinicalTrials.gov identifier: NCT02978859). 7 In an open-label phase Ib/II clinical trial, patients with anthracycline-naive soft tissue sarcoma (STS) of various histologies were randomly assigned to doxorubicin alone or in combination with olaratumab. Although median progression-free survival (PFS) was improved by 2.5 months, overall survival was markedly extended by nearly 12 months with the combination. 8 The biologic basis for this survival benefit remains uncertain, although effects on the tumor microenvironment (TME) should be explored. Olaratumab also is being studied in combination with gemcitabine and docetaxel (ClinicalTrials.gov identifier: NCT02659020) and pembrolizumab (ClinicalTrials.gov identifier: NCT03126591).
Combinations of inhibitors of dysregulated RTKs and intracellular signaling pathways may enhance antitumor activity. In malignant peripheral nerve sheath tumor (MPNST) models, the mammalian target of rapamycin (mTOR) inhibitor sirolimus was more effective in combination with pexidartinib, an inhibitor of colonystimulating factor 1 (CSF1-R) and KIT receptors, in part because pexidartinib prevented feedback activation of RTKs and phosphorylated (p) protein kinase B (AKT) from sirolimus monotherapy. 9 MPNST xenografts that received the combination showed slower tumor regrowth after treatment cessation, in part because of tumorassociated macrophage (TAM) depletion, which highlights the complex interconnections between oncogenic signaling and the immune TME. A phase I/II study is enrolling (ClinicalTrials.gov identifier: NCT02584647). A subset of targeted therapies in clinical development in sarcoma. Agents are shown within a prototypical sarcoma cancer cell according to their proposed mechanisms of action. The sarcoma subtype that is the focus of clinical study is noted beneath the agent's name, when relevant. 2-HG, 2-hydroxygluterate; aKG, alpha ketogluterate; AKT, protein kinase B; ASS1, arginosuccinate synethetase 1; CDK, cyclin-dependent kinase; CSF1-R, colony stimulating factor 1 receptor; DNMT, DNA methyltransferase; ERK, extracellular signal-regulated kinase; EZH2, enhancer of zeste homolog 2; GIST, gastrointestinal stromal tumor; HDAC, histone deacetylase; IDH1/2, mutant isocitrate dehydrogenase 1 and 2; INI1, integrase integrator (also referred to as SMARCB1); KIT, stem-cell factor receptor; LPS, liposarcoma; MEK, mitogen-activated protein kinase kinase; MPNST, malignant peripheral nerve sheath tumor; mTOR, mammalian target of rapamycin; NPC, nuclear pore complex; PDGFR-a, platelet derived growth factor receptor alpha; PI3K, phosphatidylinositol 3-kinase; PRC, polycomb repressive complex; RTKs, receptor tyrosine kinases; TCA, tricarboxylic acid cycle; TRK, tropomyosin receptor kinase (encoded by NTRK); TSPs, tumor suppressor proteins; WD/DD LPS, well-differentiated/dedifferentiated liposarcoma; XPO1, exportin 1. Abbreviations: ALK, anaplastic lymphoma kinase; aRMS, alveolar rhabdomyosarcoma; ASPS, alveolar soft part sarcoma; BET, bromodomain and extraterminal motif; CCS, clear cell sarcoma; CDK, cyclin-dependent kinase; CSF-1R, colony stimulating factor 1 receptor; DHEA, dehydroepiandrosterone; DNMT, DNA methyltransferase; eRMS, embryonal rhabdomyosarcoma; EGFR, endothelial growth factor receptor; EZH2, enhancer of zeste homolog 2; G6PD, glucose-6-phosphate dehydrogenase; GIST, gastrointestinal stromal tumor; HDAC, histone deacetylase; HSP, heat shock protein; IDH1/2, isocitrate dehydrogenase 1 and 2; IGF1R, insulin-like growth factor 1 receptor; KIT, stem-cell factor receptor; LMS, leiomyosarcoma; LPS, liposarcoma; MDM2, murine double minute 2; MEK, mitogen-activated protein kinase; MET, hepatocyte growth factor receptor; MPNST, malignant peripheral nerve sheath tumor; mTOR, mammalian target of rapamycin; NF1, neurofibromatosis type 1; PDGFR-a, platelet derived growth factor receptor alpha; PPARg, peroxisome proliferator-activated receptor gamma; PARP, poly (ADP-ribose) polymerase inhibitor; RANKL, receptor activator of nuclear factor kappa-B ligand; RET, rearranged during transfection; RTK, receptor tyrosine kinase; RTKi, receptor tyrosine kinase (small molecule); RTKmAb, receptor tyrosine kinase inhibitor (monoclonal antibody); SDH, succinate dehydrogenase; SMARCB1, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1; SS, synovial sarcoma; TRK, tropomyosin receptor kinase; VEGFR, vascular endothelial growth factor receptor; WD/DD, well-differentiated/dedifferentiated; XPO1, exportin 1. *Randomized study.
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The tropomyosin receptor kinase (TRK) RTKs are particularly relevant in neuronal development, but fusions in the related gene (NTRK) are transformative in several model systems.
10 NTRK fusions occur at low frequency in various solid tumors, including STS. In a phase I/II study of larotrectinib, a selective pan-TRK inhibitor, an objective response rate of 78% and a complete response (CR) rate of 13% were observed among patients who harbored NTRK fusions, including responses in 10 of 11 patients with sarcoma.
11,12
These findings highlight the utility of tissue-agnostic biomarkerdriven trials for rare genomic alterations.
GIST: Extending the Frontier of Personalized Medicine
In contrast to other sarcomas, oncogenesis in GIST is driven, at least initially, by activating mutations in a single RTK, most commonly KIT or PDGFR-a. Accordingly, imatinib induces dramatic responses in advanced KIT/PDGFR-a-mutant GIST. 13 Nonetheless, most patients develop imatinib resistance mediated by acquisition of multiple secondary mutations. 14 These observations suggest that broad-spectrum KIT/PDGFR-a kinase inhibitors may effectively suppress growth of diverse mutant clones.
The novel RTKi BLU-285 binds the active conformation of KIT and was efficacious in models of PDGFR-a D842V-mutant GIST, a subset with no effective therapies, and heavily pretreated KIT-mutant GIST that harbored multiple secondary mutations. 15 In a phase I dose-escalation study, BLU-285 induced partial responses in 60% of patients with D842V-mutant disease. Among those with KIT-mutant GIST, a median of four prior RTKis and various secondary mutations, partial responses occurred in 8%, and the median PFS was favorable. DCC-2618 is a novel pan-KIT and PDGFR-a switch control inhibitor; among heavily pretreated patients, the disease control rate at 6 months was 60%. 16 PDGFR-a D842V-mutant and tyrosine kinase inhibitor-refractory GIST represent major unmet therapeutic needs, and both drugs appear promising; however, additional mechanisms of resistance may emerge, and trials should include correlatives to characterize these.
ETV1 is a lineage-specific transcription factor that appears necessary for GIST oncogenesis.
17 ETV1 regulates KIT expression, and stability of ETV1 is itself regulated by mitogen-activated protein kinase (MAPK) signaling downstream from KIT, thus establishing a positive feedback loop. The combination of imatinib with inhibition of MEK, a component of the MAPK pathway, suppressed ETV1 and induced marked regressions, including CRs, in xenografts. 17 A phase Ib study of the MEK inhibitor binimetinib plus imatinib in imatinib-resistant GIST showed Choi response in five of 15 patients with RECIST-defined stable disease for 8 or more weeks in nine patients. 18 
Nuclear-Cytoplasmic Transport
The subcellular localization of intracellular proteins is essential for proper function. Exportin-1 (XPO1) is responsible for nuclear export of numerous tumor suppressors, including p21, p27, p53, and IkB (inhibitor of kappa B), which results in functional inactivation. XPO1 is frequently overexpressed in cancer, including in sarcoma. 19 Although early XPO1 inhibitors proved toxic, novel selective inhibitors of nuclear export (SINEs) are being developed.
Selinexor, a SINE compound, suppressed tumor growth in various xenografts, including GIST, LPS, leiomyosarcoma (LMS), alveolar soft-part sarcoma, and undifferentiated sarcoma. 20 In GIST, selinexor had no effect on pKIT or downstream pAKT, which implies a mechanism distinct from imatinib. 20 In WD/DD LPS, gene expression analysis showed that selinexor induced adipogenesis-related genes, including the IGF-1 binding protein IGFBP5, which suppressed IGF-1 activity. 19 In Ewing sarcoma models, which strongly overexpress XPO1, selinexor suppressed expression of the EWS-FLI1 fusion oncoprotein. 21 Selinexor was evaluated in a phase Ib sarcoma study. 22 Although no objective responses occurred, 40% of patients with DD LPS showed some decrease in target lesion size, and 47% had stable disease for 4 or more months. A registration-directed study in DD LPS is ongoing (ClinicalTrials.gov identifier: NCT02606461).
Because selinexor modulates subcellular localization of multiple tumor suppressors and thus influences various cellular processes, a plethora of combinations could be explored. Sarcoma cell lines appear variably sensitive to selinexor, with 50% inhibitory concentrations that range from 50 nM for DD LPS to 1,500 nM for Ewing sarcoma. 23 The effects of selinexor in sarcoma appear partially mediated by nuclear retention of IkB, which inhibits NFkB transcriptional activity and results in decreased levels of the antiapoptotic protein survivin. 23 Unlike SINEsensitive cell lines, SINE-resistant models, such as Ewing sarcoma, fail to localize IkB to the nucleus upon selinexor monotherapy but could be sensitized through addition of a proteasome inhibitor, which would prevent degradation of IkB. In relatively SINEresistant MPNST xenografts, selinexor suppressed growth by 30%, but addition of the proteasome inhibitor carfilzomib increased this effect to 65%.
23

Metabolism
Many oncogenic signaling pathways reprogram cellular metabolism in support of the malignant phenotype, and metabolism is an emerging hallmark of cancer.
24,25 Chondrosarcoma, the second most common bone sarcoma, is chemotherapy resistant.
26
Mutations in the genes for isocitrate dehydrogenase (IDH) 1 and 2, initially described in glioma and acute myeloid leukemia, occur in 56% of conventional chondrosarcomas.
27,28 These enzymes normally catalyze conversion of isocitrate to alpha-ketogluterate (a-KG). Mutant IDH1/2 (mIDH1/2) are gain-of-function enzymes that instead produce an oncometabolite, 2-hydroxygluterate (2-HG), from a-KG.
29
Several oncogenic properties of 2-HG, including epigenetic repression of genes essential for differentiation, have been described. 29 In chondrosarcoma cell lines, mIDH induces 2-HG-dependent DNA hypermethylation, impairment of differentiation, loss of contact inhibition, and tumor formation in vivo, whereas differentiation could be restored by the hypomethylating agent 5-azacitidine, which supports an epigenetic mechanism for mIDH. 30 In a phase I study of AG120, an mIDH1 inhibitor, a best response of stable disease was observed for 11 of 20 patients with chondrosarcoma, and 3-month PFS was 58%.
31
Many tumors appear dependent on the amino acid glutamine. The glutaminase inhibitor CB-839 showed promise in mIDH chondrosarcoma cell lines and neurofibromatosis type 1-mutant sarcoma models. 32, 33 In both cases, efficacy was associated with mTOR suppression, which reflects the role of mTOR in the balance of growth signals with nutrient availability-a checkpoint many cancers abrogate. 24 The enzyme arginosuccinate synthetase 1 (ASS1) converts citrulline and aspartate to arginine. Loss of ASS1 supports increased nucleotide and protein biosynthesis needed by tumors but renders them dependent on extracellular arginine. Almost 90% of sarcomas exhibit low ASS1 expression. 34 Treatment of ASS1 low sarcoma cell lines with pegylated arginine deaminase (ADI-PEG20), which depletes extracellular arginine, induced cytostasis and autophagy; however, unlike other solid tumors, most sarcoma models eventually subverted arginine starvation through reexpression of ASS1. 34 The combination of ADI-PEG20 with chloroquine, an inhibitor of autophagy, showed synthetic lethality in ASS1 low cell lines.
34
Furthermore, ASS1-deficient tumors deprived of arginine showed increased reliance on glutamine. 35 Targeting this compensatory upregulation by addition of a glutaminase inhibitor to ADI-PEG20 resulted in synthetic lethality in several models, including LMS. 35 
Epigenetics
Histone deacetylase inhibitors showed preclinical promise in sarcoma and particularly in translocation-related subtypes, including Ewing sarcoma. However, histone deacetylase inhibitor monotherapy was unsuccessful in trials that enrolled patients with unselected sarcomas.
36 New mechanism-based therapies that reflect abnormalities in specific epigenetic regulators appear more promising. Enhancer of zeste homolog 2 (EZH2) is a component of the polycomb repressive complex (PRC2) and participates in chromatin remodeling through trimethylation of histone H3K27, which results in gene silencing at loci involved in determination of cell fate. 37, 38 The SWI/SNF complex also remodels chromatin and often opposes PRC2-mediated silencing. 39 This balance is shifted in favor of oncogenesis upon mutation or overexpression of EZH2 or loss of a key SWI/SNF component, SMARCB1 (SWI/SNFrelated matrix-associated actin-dependent regulator of chromatin subfamily B member 1), which effectively results in EZH2 hyperactivity. A phase II trial of the EZH2 inhibitor tazemetostat is enrolling cohorts of solid tumors with SMARCB1 loss. Epithelioid sarcoma is a rare, aggressive sarcoma in which functional loss of SMARCB1 is especially common. 40 Among 31 patients with epithelioid sarcoma, the overall response rate was 13%, and the median PFS was 5.7 months.
41
In translocation-related subtypes such as Ewing sarcoma, fusion oncoproteins result in widespread dysregulation of gene expression. The novel plasmid DNA construct pbi-shRNA EWS/ FLI1 lipoplex incorporates siRNA and miRNA effectors directed at EWS-FLI1 mRNA. The agent prolonged survival in Ewing sarcoma xenografts.
42,43
REALIZING THE PROMISE OF IMMUNOTHERAPY FOR SARCOMA
Novel Combinations of Checkpoint Inhibitors
Agents that target the programmed death 1 (PD-1) receptor and its ligand (PD-L1) have transformed the treatment of many solid tumors, but adoption has been slow in STS. 44 Efforts are underway to determine which patients with STS will respond to these agents. [45] [46] [47] Undifferentiated pleomorphic sarcoma (UPS), a subtype with a higher mutational burden, also has a relatively high T-cell fraction and high levels of PD-1 and PD-L1. The SARC028 trial of single-agent pembrolizumab suggested a potential benefit for UPS, with a response rate of 40%, which was higher than other subtypes. 48 Conversely, the translocation-related subtypes synovial sarcoma (SS) and myxoid/round cell liposarcoma (MRCL) have an immunologically quiet TME and appear less responsive to anti-PD-1 monotherapy. 49 LMS exhibits both PD-L1 expression and T-cell infiltration; however, a study of nivolumab in advanced uterine LMS revealed little activity. 50 Interestingly, in one patient whose disease responded, a PTEN mutation may have induced resistance. 51 Cytotoxic T-cell lymphocyte-4 inhibition with anti-PD-1 therapy improved survival for patients with melanoma, although they had more toxicity. 52 A study that combined nivolumab with a reduced dose of ipilimumab (1 mg/kg) showed impressive clinical activity for the combination. 53 Expansion cohorts to further evaluate this approach are planned for UPS and DD LPS, in which promising results were seen.
Although these initial studies are encouraging, novel combinations to exploit both established and untested targets may be necessary to induce consistent and durable responses. The RTKi axitinib may encourage T-cell trafficking into the TME and is being tested with pembrolizumab (ClinicalTrials.gov identifier: NCT02636725). Gemcitabine may have a similar impact by modulating vasculature in addition to direct cytotoxic effects. Doxorubicin may achieve tumor degradation and antigen presentation with relatively low levels of lymphodepletion. Both chemotherapies are being studied with pembrolizumab (ClinicalTrials.gov identifiers: NCT03123276 and NCT02888665).
Given the slow pace of development for checkpoint inhibitors in sarcoma compared with other cancers, the field must be quicker to test novel targets, such as B7-H3, OX40, GITR, and ICOS. [54] [55] [56] [57] Compounds that target the inhibitory transforming growth factor beta could be combined with these agents. New cytokine formulations, such as pegylated interleukin-2 (IL-2), may work well in combination with checkpoint strategies.
58 PD-1 inhibitors are being tested in other clinical settings, including neoadjuvant settings, in the multicenter SARC032 study.
Anti-Macrophage
TAMs often are characterized as classically (M1) or alternatively (M2) activated. These monocyte-derived cells can shift phenotype and function on a spectrum between the two extremes.
59 M1 TAMs present antigen to T cells and harbor high class II human leukocyte antigen (HLA) expression. They directly lyse tumor cells and secrete tumor necrosis factor and IL-12. M2 TAMs express CD115, CD163, and CD206; support tumor growth; produce IL-10; and promote angiogenesis. Although TAMs likely are important for many types of sarcoma, 60,61 their role has been highlighted in LMS. [62] [63] [64] Because TAMs are ubiquitous and appear important for immune evasion, agents that deplete TAMs or that convert their phenotype from M2 to M1 are desirable. Pexidartinib is an RTKi selective for CSF-1R, c-FMS (CD115), and c-KIT. 9 A phase I study combining pexidartinib with sirolimus is recruiting patients with unresectable sarcomas (ClinicalTrials.gov identifier: NCT02584647). A humanized anti-CD47 monoclonal antibody (Hu5F9-G4) that promotes macrophage phagocytosis also is being studied (ClinicalTrials.gov identifier: NCT02216409). 65 Glucopyranosyl lipid A, a Toll-like receptor 4 agonist with a similar impact on TAMs that also can recruit T cells to the TME, is being tested in combination with radiotherapy to increase tumor antigen release (ClinicalTrials.gov identifier: NCT02180698). Interestingly, PD-1 and PD-L1 expression have been correlated with TAM infiltration. 66 On the basis of anti-TAM activity observed with the US Food and Drug Administration-approved agent trabectedin, 67, 68 trials that combine trabectedin with checkpoint inhibitors are ongoing (ClinicalTrials.gov identifiers: NCT03074318, NCT03138161).
Cellular Therapies
Chimeric antigen receptors (CARs) that target CD19 + lymphoid malignancies, particularly acute lymphoblastic leukemia, have shown greater than 90% CR rates. 69 These receptors consist of an extracellular antigen recognition domain coupled via transmembrane domains to the CD3z chain of the T-cell receptor (TCR), in addition to the CD28 and/or 41BB costimulatory receptors (Fig 2) . CARs target cell-surface proteins independent of HLA type. However, the identification of promising targets for CARs is challenging; many groups have pursued such targets for monoclonal antibodies with limited success. Therefore, few trials to evaluate these exciting receptors are underway in solid tumors. In one study, CAR T cells that target human epidermal growth factor receptor 2 were used for patients with osteosarcoma and Ewing sarcoma, and treatment resulted in tumor necrosis. 70 CARs that target the immune checkpoint B7-H3 as well as GD-2 are being tested (ClinicalTrials.gov identifiers: NCT00902044, NCT02107963, NCT01953900).
High-affinity TCRs can recognize intracellular proteins, which allows for many more potential targets. However, because target recognition requires presentation on the cell surface by major histocompatibility molecules, TCRs have HLA specificity. NY-ESO-1 is a cancer germ-line antigen and an ideal target for T-cell therapy because of its immunogenicity and cancer specificity. NY-ESO-1 is expressed homogenously by most SS and MRCL tumors.
71,72 In a pilot study to test a high-affinity NY-ESO-1 specific TCR, responses were seen in the majority of patients. 73, 74 TCRs that target MAGE-A3, MAGE-A4, and MAGE-A10 also are in clinical trials (ClinicalTrials.gov identifiers: NCT03132922, NCT02989064, NCT03139370, NCT02111850, NCT02153905). Antigen-specific T-cells can be purified and cultured from the blood of patients with STS (ClinicalTrials.gov identifier: NCT01477021). 75 Approaches to target multiple antigens (NY-ESO-1, MAGE family, and PRAME) by using this method are being tested at Baylor (ClinicalTrials.gov identifier: NCT02239861). The utility of natural killer cells is being studied in the context of haploidentical allogeneic transplantation (ClinicalTrials.gov identifiers: NCT02409576, NCT02100891), as well as outside of the transplantation setting (ClinicalTrials.gov identifier: NCT02890758). Dendritic cells (DCs) pulsed with sarcoma tumor lysate can induce antitumor immunity and clinical responses. This approach is being evaluated with gemcitabine (ClinicalTrials.gov identifier: NCT01803152). 76, 77 Specific targets also could be used instead of tumor lysate (ClinicalTrials.gov identifier: NCT03034304).
Vaccines
Vaccines (including the DC-based therapies described in the previous paragraph) work by stimulating the patient's endogenous immune response. Although the concept of vaccination of patients against cancer-specific proteins is old, new approaches are reinvigorating this strategy. The most basic approach to vaccination is through subcutaneous administration of cancer-specific peptides. For example, a trivalent peptide vaccine against ganglioside antigens was used in a placebocontrolled, multicenter trial that included 136 patients with melanoma or sarcoma and no evidence of disease after metastasectomy. 78 Although more serologic responses were seen after vaccination, there was no significant difference in PFS between trial arms. A pilot study to use peptides that spanned the SYT-SSX fusion in patients with SS resulted in one transient response. 79 Priming naive CD8 + T-cells requires interaction with activated DCs that present antigens via major histocompatibility complex I. Presentation of antigen expressed in the cytoplasm may induce a more potent CD8 + T-cell response compared with exogenously delivered peptides. 80 A new class of vaccines that uses an integration-deficient lentiviral vector to selectively target CD209 on DCs via its envelope glycoprotein derived from Sindbis virus 81, 82 appears to induce strong T-cell responses in trials that target NY-ESO-1 in SS and MRCL. 83, 84 Phase I/II studies of this vaccine showed impressive results, including a 1-year overall survival of 82%. Combination of this vaccine with a Toll-like receptor 4 agonist and protein vaccine resulted in even deeper antibody and CD4 + T-cell responses (ClinicalTrials.gov identifier: NCT02387125). 85 This combination was evaluated recently with a PD-L1 inhibitor (ClinicalTrials.gov identifier: NCT02609984).
Another DC-targeted vaccine strategy used a monoclonal antibody to target CD205 bound to full length NY-ESO-1 protein and resulted in T-cell responses in a pilot study with multiple tumors, including sarcoma. 86 
Oncolytic Viral Therapies
Talimogene laherparepvec, an oncolytic virus approved by the US Food and Drug Administration for melanoma, may be well suited to STS, because sarcomas are superficial and, thus, injectable at bedside. 87 This strategy is being investigated in an ongoing study at the University of Iowa (ClinicalTrials.gov identifier: NCT02453191). The addition of anti-PD-1 in the metastatic setting may potentiate activity upon the sarcoma TME (ClinicalTrials.gov identifier: NCT03069378). Early signals of clinical activity may justify trials of viruses being evaluated in other malignancies (ClinicalTrials.gov identifiers: NCT02143804, NCT02705196).
In conclusion, both the rarity and the molecular heterogeneity of sarcoma create challenges for the development of nonchemotherapy-based therapeutics. However, recent findings that a substantial subset of sarcomas harbor potentially targetable genetic alterations, and a deepening understanding of the sarcoma immune microenvironment, should accelerate clinical translational research in this field. 49, 88 Indeed, as evidenced by therapies such as olaratumab, trabectedin, and denosumab, efforts to capitalize on insights into subtype-specific cancer biology have already met with clinical success, and there exists great promise to expand the range of targeted and immune-based treatments for patients with this disease.
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